CriticalAntidepressants. Other antidepressants of herbal origin×Selective irreversible monoamine oxidase B inhibitor
Updated · Methodology
Mechanism
Rasagiline irreversibly and selectively inhibits monoamine oxidase type B (MAO-B) (rasagiline summary of product characteristics, SmPC, European Medicines Agency, EMA, section 5.1). The rasagiline SmPC lists St John's wort among other MAO inhibitors and warns that combining rasagiline with them may cause non-selective MAO inhibition, which can lead to a hypertensive crisis (rasagiline SmPC, EMA, sections 4.3 and 4.5). According to the Spanish St John's wort SmPC, St John's wort extract is an antidepressant that inhibits the reuptake of serotonin, noradrenaline and dopamine (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). The US rasagiline label cites reports of serotonin syndrome in people taking antidepressants with selective MAO-B inhibitors, including rasagiline (rasagiline label, US Food and Drug Administration, FDA, section 5.2). There is also a pharmacokinetic route: CYP1A2 is the main enzyme that metabolises rasagiline (rasagiline SmPC, EMA, section 5.2). The Spanish St John's wort SmPC lists CYP1A2 among the enzymes that St John's wort induces and reports lower rasagiline levels with a risk of treatment failure (St John's wort SmPC, AEMPS, section 4.5). According to the rasagiline SmPC, CYP1A2 induction, for example in smokers, may lower rasagiline blood levels (rasagiline SmPC, EMA, section 4.5).
Symptoms
According to the rasagiline documents, the main danger of the combination is a hypertensive crisis caused by non-selective monoamine oxidase (MAO) inhibition (rasagiline summary of product characteristics, SmPC, European Medicines Agency, EMA, section 4.5; rasagiline label, US Food and Drug Administration, FDA, section 7.3). The US label lists the signs of serotonin syndrome with rasagiline and antidepressants: confusion, agitation, hallucinations, shivering, sweating, fever, high blood pressure, fast heart rate, nausea, diarrhoea, muscle rigidity and twitching, hyperreflexia and tremor. The label adds that the syndrome can be fatal (FDA rasagiline label, section 5.2). The Spanish St John's wort SmPC also lists lower rasagiline levels with a risk of treatment failure (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Parkinson's disease symptoms, the reason rasagiline is prescribed, may then be less well controlled (rasagiline SmPC, EMA, section 4.1).
Management
The combination is contraindicated. The rasagiline summary of product characteristics (SmPC) contraindicates rasagiline with other monoamine oxidase (MAO) inhibitors, including non-prescription medicines and natural products, and names St John's wort explicitly among them (rasagiline SmPC, European Medicines Agency, EMA, sections 4.3 and 4.5). The US rasagiline label contraindicates St John's wort by name (rasagiline label, US Food and Drug Administration, FDA, section 4). The Spanish St John's wort SmPC says St John's wort must not be taken with antidepressants, particularly MAO inhibitors. Its interaction table lists rasagiline among medicines that must not be taken with St John's wort (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). The authorisation of that product has been suspended since 11 June 2026, and there is no other current Spanish St John's wort SmPC. At least 14 days must pass between stopping rasagiline and starting an MAO inhibitor, and the rasagiline SmPC places St John's wort in that group (rasagiline SmPC, EMA, section 4.3). No document says how long to wait between the last dose of St John's wort and the start of rasagiline.
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Azilect (rasagiline) prescribing information – contraindications with sympathomimetics (2014)– FDA Azilect label, Drug Interactions §7.1; concurrent triptan use cautioned; DailyMed setid a40d0e73-3f9f-4b01-979d-402c9cdaeb60
- EMA: Ficha técnica: Rasagilina – Azilect (EU/1/04/304), sección 4.3 (2025)– EMA, SmPC Azilect 1 mg (EU/1/04/304), texto en CIMA nº 04304004, información del producto actualizada 08/04/2025, secciones 4.3, 4.5, 5.1 y 5.2
- EMA: Ficha técnica: Rasagilina – Azilect (EU/1/04/304), sección 4.5 (2025)– EMA, SmPC Azilect 1 mg (EU/1/04/304), texto en CIMA nº 04304004, consultado 19.10.2026, sin fecha de revisión en CIMA, secciones 4.4, 4.5, 5.1 y 5.2
- AEMPS: Ficha técnica: Hipérico (Hypericum perforatum) (nº registro 79963), secciones 4.3 y 4.5 (2025)– AEMPS, CIMA, Hipérico Arkopharma cápsulas duras, nº registro 79963, documento 11/2025 (fecha de revisión del texto 09/2016), secciones 4.3, 4.4 y 4.5; autorización suspendida desde el 11.06.2026, única ficha técnica de hipérico no revocada en CIMA